| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013NatCo...4.2185V |
| P356 | DOI | 10.1038/NCOMMS3185 |
| P698 | PubMed publication ID | 23887589 |
| P50 | author | Manuel Sobrinho Simões | Q10324505 |
| Paula Soares | Q37840702 | ||
| Ana Preto | Q38319577 | ||
| Hugo Prazeres | Q38327996 | ||
| João Vinagre | Q38328016 | ||
| José Manuel Lopes | Q42913152 | ||
| Rui Manuel Reis | Q49550849 | ||
| Valdemar Maximo | Q52726295 | ||
| Adriana Gaspar da Rocha | Q59087043 | ||
| Vasco Sampaio-Pinto | Q60633171 | ||
| José Manuel Cameselle-Teijeiro | Q91272191 | ||
| Joana Lyra | Q117271490 | ||
| P2093 | author name string | Helena Pópulo | |
| Rui Batista | |||
| Jorge Lima | |||
| Ana Almeida | |||
| Miguel Melo | |||
| Patrícia Castro | |||
| Ricardo Celestino | |||
| Lúcio Lara Santos | |||
| Fernando Pardal | |||
| Ligia Castro | |||
| Luis Lima | |||
| Ricardo Coelho | |||
| P2860 | cites work | Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi | Q24646052 |
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Highly recurrent TERT promoter mutations in human melanoma | Q29614798 | ||
| TERT promoter mutations in familial and sporadic melanoma | Q29614920 | ||
| Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas | Q35731037 | ||
| Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. | Q36713512 | ||
| TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal | Q36762656 | ||
| Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors. | Q36809668 | ||
| Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells | Q39634789 | ||
| Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma | Q43154862 | ||
| Relevance of Urine Telomerase in the Diagnosis of Bladder Cancer | Q59300443 | ||
| Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas | Q60527002 | ||
| BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC | Q60527142 | ||
| Diagnosis of gastrointestinal stromal tumors: A consensus approach | Q74400164 | ||
| Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer | Q84818818 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2185 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Frequency of TERT promoter mutations in human cancers | |
| P478 | volume | 4 |
| Q90676310 | A comprehensive expression landscape of RNA-binding proteins (RBPs) across 16 human cancer types |
| Q42669039 | A method to reduce ancestry related germline false positives in tumor only somatic variant calling |
| Q37106836 | A novel truncated form of HMGA2 in tumors of the ovaries |
| Q30459853 | A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression |
| Q38849194 | A second chance for telomerase reverse transcriptase in anticancer immunotherapy |
| Q39163637 | A six-genotype genetic prognostic model for papillary thyroid cancer |
| Q40368515 | A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers |
| Q54567836 | Absence of TERT promoter mutations in colorectal precursor lesions and cancer. |
| Q54379905 | Absence of TERT promoter mutations in esophageal adenocarcinoma. |
| Q54195627 | Absence of TERT promoter mutations in pituitary adenomas. |
| Q52885754 | Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma. |
| Q103836778 | Advances in bladder cancer biology and therapy |
| Q38838144 | Altered TERT promoter and other genomic regulatory elements: occurrence and impact |
| Q38820649 | An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations |
| Q64062715 | Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities |
| Q35441872 | Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer |
| Q54974707 | Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast. |
| Q36221232 | Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis |
| Q27853042 | BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence |
| Q92904521 | BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry |
| Q37109755 | BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients |
| Q59333141 | BRD4 and Cancer: going beyond transcriptional regulation |
| Q55306707 | Beginning at the ends: telomeres and human disease. |
| Q38645015 | Beyond the exome: the role of non-coding somatic mutations in cancer |
| Q38954099 | Biologic and Clinical Perspectives on Thyroid Cancer |
| Q47304287 | Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastomas |
| Q47386898 | Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential. |
| Q61800627 | Bring It to an End: Does Telomeres Size Matter? |
| Q49233052 | CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension |
| Q31144723 | Cancer somatic mutations cluster in a subset of regulatory sites predicted from the ENCODE data |
| Q38395966 | Cancer whole-genome sequencing: present and future. |
| Q93043617 | Cancer-Associated Mutations but No Cancer: Insights into the Early Steps of Carcinogenesis and Implications for Early Cancer Detection |
| Q26738705 | Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications |
| Q30459452 | Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer |
| Q38874534 | Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. |
| Q41877927 | Cell populations can use aneuploidy to survive telomerase insufficiency |
| Q36078151 | Challenges in identifying cancer genes by analysis of exome sequencing data. |
| Q90134925 | Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients |
| Q47916891 | Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. |
| Q55026989 | Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. |
| Q39937053 | Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas |
| Q35906046 | Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer |
| Q36560914 | Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation |
| Q52611832 | Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. |
| Q95840207 | Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC) |
| Q38687220 | Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis |
| Q55436824 | Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. |
| Q57210092 | Coexistence of Promoter Mutations and the V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients |
| Q40857012 | Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness |
| Q57797239 | Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behaviour of bladder cancer |
| Q48677433 | Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma |
| Q92193184 | Continuous culture of urine-derived bladder cancer cells for precision medicine |
| Q37079525 | Copy Number Profiling of Brazilian Astrocytomas |
| Q97527459 | Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis |
| Q38614394 | Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses? |
| Q37741228 | Current Insights to Regulation and Role of Telomerase in Human Diseases. |
| Q64965411 | Deep learning sequence-based ab initio prediction of variant effects on expression and disease risk. |
| Q92887487 | Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes |
| Q55003880 | Detection of Aberrant TERT Promoter Methylation by Combined Bisulfite Restriction Enzyme Analysis for Cancer Diagnosis. |
| Q35055107 | Development and characterization of six new human papillary thyroid carcinoma cell lines. |
| Q40437085 | Development of software and modification of Q-FISH protocol for estimation of individual telomere length in immunopathology |
| Q27853057 | Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. |
| Q64068854 | Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma |
| Q38461565 | Diagnostic, prognostic and predictive relevance of molecular markers in gliomas |
| Q89802978 | Differential Allele-Specific Expression Uncovers Breast Cancer Genes Dysregulated by Cis Noncoding Mutations |
| Q35600108 | Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature. |
| Q91385901 | Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner |
| Q34306010 | Diverse modes of genomic alteration in hepatocellular carcinoma |
| Q92664567 | Diverse regulatory manners of human telomerase reverse transcriptase |
| Q100526089 | Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations |
| Q97419111 | Dysregulation of cancer genes by recurrent intergenic fusions |
| Q26778154 | ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome |
| Q47224965 | ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression |
| Q52564490 | Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody. |
| Q97424494 | Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression |
| Q38997020 | Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations |
| Q36319724 | Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer |
| Q37136357 | Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. |
| Q47131430 | European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics |
| Q38734366 | Evolving Molecular Genetics of Glioblastoma |
| Q33917659 | Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma |
| Q47586814 | Expression of the human telomerase reverse transcriptase gene is modulated by quadruplex formation in its first exon due to DNA methylation |
| Q50163635 | Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management |
| Q54190292 | Frequency of TERT promoter mutations in primary tumors of the liver. |
| Q90480926 | Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy |
| Q37624069 | Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. |
| Q34375331 | FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer |
| Q28394370 | Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma |
| Q91289304 | GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression |
| Q38862963 | Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset |
| Q28073241 | Genetic alterations in hepatocellular carcinoma: An update |
| Q41195725 | Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast |
| Q93096373 | Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma |
| Q48291446 | Genetic landscape of papillary thyroid carcinoma in the Chinese population. |
| Q34449957 | Genetics of familial melanoma: 20 years after CDKN2A. |
| Q86048225 | Genetics: The genomic landscape of papillary thyroid carcinoma |
| Q41842692 | Genome-wide analysis of noncoding regulatory mutations in cancer |
| Q30838341 | Genome-wide prediction of cancer driver genes based on SNP and cancer SNV data |
| Q49197249 | Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas. |
| Q92372118 | Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma |
| Q52647646 | Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. |
| Q92830555 | Genomics-Enabled Precision Medicine for Cancer |
| Q34667738 | Genotyping of cutaneous melanoma |
| Q92500797 | Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer |
| Q38460865 | Glioblastoma: pathology, molecular mechanisms and markers |
| Q31159221 | Global inference of disease-causing single nucleotide variants from exome sequencing data |
| Q36599690 | Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling |
| Q99708104 | Heterogeneity of telomerase reverse transcriptase mutation and expression, telomerase activity and telomere length across human cancer cell lines cultured in vitro |
| Q36103321 | High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma |
| Q41156947 | Hotspot TERT promoter mutations are rare events in testicular germ cell tumors. |
| Q26745549 | Human Specific Regulation of the Telomerase Reverse Transcriptase Gene |
| Q35840001 | Identification of High-Impact cis-Regulatory Mutations Using Transcription Factor Specific Random Forest Models |
| Q52620813 | Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. |
| Q51415479 | In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. |
| Q36850060 | Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. |
| Q52644147 | Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. |
| Q49843050 | Insights about genome function from spatial organization of the genome. |
| Q47239342 | Insights from human genetic studies of lung and organ fibrosis |
| Q37376448 | Integrative analysis reveals clinical phenotypes and oncogenic potentials of long non-coding RNAs across 15 cancer types |
| Q47745006 | Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas |
| Q39441277 | Intrinsic Molecular Processes: Impact on Mutagenesis |
| Q36676636 | LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations |
| Q37449688 | Lack of TERT Promoter Mutations in Human B-Cell Non-Hodgkin Lymphoma |
| Q34046731 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences |
| Q58561861 | Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population |
| Q43540329 | Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers |
| Q47702648 | Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms |
| Q36695151 | Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). |
| Q35911314 | Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression |
| Q38987554 | Means to the ends: The role of telomeres and telomere processing machinery in metastasis |
| Q52727349 | Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. |
| Q34044830 | Melanoma genetics |
| Q35584856 | Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology |
| Q55027570 | MiR-497-5p, miR-195-5p and miR-455-3p function as tumor suppressors by targeting hTERT in melanoma A375 cells. |
| Q91761497 | Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas |
| Q92330277 | Modelling TERT regulation across 19 different cancer types based on the MIPRIP 2.0 gene regulatory network approach |
| Q33624558 | Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis. |
| Q45143637 | Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. |
| Q48088782 | Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation |
| Q38833275 | Molecular genetics of thyroid cancer. |
| Q47295202 | Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. |
| Q53190179 | Molecular perspectives in differentiated thyroid cancer. |
| Q26741086 | Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks |
| Q52691469 | Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers. |
| Q41143039 | Mutation of the TERT promoter leads to poor prognosis of patients with non-small cell lung cancer |
| Q30459839 | Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers |
| Q64058147 | Mutation profiles of follicular thyroid tumors by targeted sequencing |
| Q40077046 | Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center |
| Q33688915 | Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas |
| Q34499917 | NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings. |
| Q47212889 | NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features |
| Q93088940 | Neural Stem Cells of the Subventricular Zone as the Origin of Human Glioblastoma Stem Cells. Therapeutic Implications |
| Q42251890 | Non-coding cancer driver candidates identified with a sample- and position-specific model of the somatic mutation rate |
| Q58134002 | Non-coding genetic variation in cancer |
| Q90348520 | Non-duplex G-Quadruplex Structures Emerge as Mediators of Epigenetic Modifications |
| Q58550783 | Not the same thing: metastatic PTCs have a different background than ATCs |
| Q37030289 | Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma |
| Q28269966 | ORegAnno 3.0: a community-driven resource for curated regulatory annotation |
| Q34474391 | OncoCis: annotation of cis-regulatory mutations in cancer |
| Q41168032 | Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. |
| Q58806002 | Overlapping open reading frames strongly reduce human and yeast STN1 gene expression and affect telomere function |
| Q37729676 | Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge |
| Q38176686 | Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic? |
| Q27027491 | Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations |
| Q50105699 | Precision oncology in the age of integrative genomics. |
| Q49803880 | Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas |
| Q48203042 | Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. |
| Q37221898 | Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India |
| Q38184374 | Prognostic biomarkers in thyroid cancer |
| Q38416278 | Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. |
| Q47418685 | Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma |
| Q36107360 | Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis |
| Q26796901 | RAS proto-oncogene in medullary thyroid carcinoma |
| Q26769014 | Reactivation of telomerase in cancer |
| Q52608306 | Reconstructing the molecular life history of gliomas. |
| Q47719683 | Reconstruction of enhancer-target networks in 935 samples of human primary cells, tissues and cell lines |
| Q35743608 | Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. |
| Q35797838 | Recurrent somatic mutations in regulatory regions of human cancer genomes |
| Q40089376 | Regulation of Telomere Homeostasis during Epstein-Barr virus Infection and Immortalization. |
| Q91522991 | Regulation of human telomerase in homeostasis and disease |
| Q60690261 | Regulatory variants: from detection to predicting impact |
| Q64243404 | Revisiting Telomere Shortening in Cancer |
| Q36971261 | Role of Telomeres and Telomerase in Aging and Cancer |
| Q90836884 | Role of a Promoter Mutation in TERT in Malignant Transformation of Pleomorphic Xanthoastrocytoma |
| Q26744271 | Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies |
| Q33853615 | SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma |
| Q59332881 | SMuRF: a novel tool to identify regulatory elements enriched for somatic point mutations |
| Q92509226 | Saturation mutagenesis of twenty disease-associated regulatory elements at single base-pair resolution |
| Q58746202 | Sc-ncDNAPred: A Sequence-Based Predictor for Identifying Non-coding DNA in |
| Q92282098 | Scarcity of Recurrent Regulatory Driver Mutations in Colorectal Cancer Revealed by Targeted Deep Sequencing |
| Q43274590 | Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma |
| Q64087532 | Sequencing and curation strategies for identifying candidate glioblastoma treatments |
| Q42077071 | Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations. |
| Q92596277 | Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer |
| Q57943504 | Successful Targeted Therapy of Refractory Pediatric Fusion-Positive Secretory Breast Carcinoma |
| Q54310538 | Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. |
| Q41521817 | Systematic analysis of telomere length and somatic alterations in 31 cancer types. |
| Q98771221 | TERT Promoter Mutation C228T Increases Risk for Tumor Recurrence and Death in Head and Neck Cancer Patients |
| Q89551068 | TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients |
| Q42748231 | TERT Promoter Mutations Enhance Telomerase Activation by Long-Range Chromatin Interactions |
| Q38744769 | TERT Promoter Mutations in Thyroid Cancer |
| Q37408393 | TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis |
| Q40858851 | TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. |
| Q33414576 | TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities |
| Q47339267 | TERT promoter hotspot mutations in breast cancer. |
| Q54347306 | TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. |
| Q49957857 | TERT promoter mutation in adult granulosa cell tumor of the ovary. |
| Q54220234 | TERT promoter mutation is uncommon in acral lentiginous melanoma. |
| Q27853068 | TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma |
| Q88962020 | TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine |
| Q40354589 | TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors |
| Q34654382 | TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma |
| Q36962382 | TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas |
| Q43119423 | TERT promoter mutations and monoallelic activation of TERT in cancer |
| Q35833084 | TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. |
| Q33682388 | TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer |
| Q50053390 | TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases |
| Q34313648 | TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
| Q38383121 | TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. |
| Q36415418 | TERT promoter mutations are a rare event in gastrointestinal stromal tumors |
| Q90238429 | TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma |
| Q35048963 | TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma |
| Q37316068 | TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma |
| Q54314475 | TERT promoter mutations in clear cell renal cell carcinoma. |
| Q37093384 | TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes |
| Q33688439 | TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas |
| Q42456732 | TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. |
| Q26770808 | TERT promoter mutations in thyroid cancer |
| Q33769095 | TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas |
| Q28397245 | TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas |
| Q44378342 | TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer |
| Q90749197 | TERT, a promoter of CNS malignancies |
| Q92078216 | TERTp Mutation Detection in Plasma by Droplet-Digital Polymerase Chain Reaction in Spinal Myxopapillary Ependymoma with Lung Metastases |
| Q89287810 | TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma |
| Q42357870 | Taking the brakes off telomerase |
| Q41233717 | Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma |
| Q53688274 | Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia. |
| Q60917015 | Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma |
| Q98177214 | Targeting telomerase for cancer therapy |
| Q28068238 | Telomerase Activation in Hematological Malignancies |
| Q36514657 | Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi |
| Q51304058 | Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas. |
| Q92755895 | Telomerase and Telomeres Biology in Thyroid Cancer |
| Q64911093 | Telomerase and Telomeres in Endometrial Cancer. |
| Q98386412 | Telomerase inhibition decreases esophageal squamous carcinoma cell migration and invasion |
| Q38232447 | Telomerase promoter mutations in cancer: an emerging molecular biomarker? |
| Q55122468 | Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia. |
| Q36857933 | Telomerase reactivation in cancers: Mechanisms that govern transcriptional activation of the wild-type vs. mutant TERT promoters |
| Q47764734 | Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer |
| Q37596836 | Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. |
| Q47266315 | Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer. |
| Q55220796 | Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors. |
| Q46754264 | Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients |
| Q53232555 | Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. |
| Q91028354 | Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population |
| Q37317414 | Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. |
| Q54374929 | Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. |
| Q37395716 | Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression |
| Q34396480 | Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma |
| Q26739948 | Telomerase: The Devil Inside |
| Q50131917 | Telomere Length Dynamics and the Evolution of Cancer Genome Architecture |
| Q55443450 | Telomere Maintenance Mechanisms in Cancer. |
| Q26744808 | Telomere and Telomerase Therapeutics in Cancer |
| Q33613946 | Telomere biology and translational research. |
| Q34426966 | Telomere maintenance mechanisms in cancer: clinical implications |
| Q52714796 | Telomere sequence content can be used to determine ALT activity in tumours. |
| Q34784471 | Telomere-regulating genes and the telomere interactome in familial cancers. |
| Q89976278 | Telomeres and Telomere Length: A General Overview |
| Q39413214 | Telomeres and telomerase in prostate cancer development and therapy. |
| Q34555986 | The ETS family of oncogenic transcription factors in solid tumours. |
| Q39403393 | The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications |
| Q90682184 | The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA |
| Q60909457 | The Power of Fish Models to Elucidate Skin Cancer Pathogenesis and Impact the Discovery of New Therapeutic Opportunities |
| Q90596932 | The Solo Play of TERT Promoter Mutations |
| Q33709979 | The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors |
| Q52594766 | The association of NF2 (neurofibromin 2) gene polymorphism and the risk of medulloblastomas. |
| Q26753387 | The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations |
| Q89828444 | The hTERT core promoter forms three parallel G-quadruplexes |
| Q90009351 | The mTOR pathway is necessary for survival of mice with short telomeres |
| Q35023231 | The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing |
| Q38903424 | The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. |
| Q90339275 | The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer |
| Q93117015 | The role of telomeres and telomerase in cirrhosis and liver cancer |
| Q26781886 | The search for cis-regulatory driver mutations in cancer genomes |
| Q38564090 | The utility of molecular markers in pre-operative assessment of thyroid nodules |
| Q90744618 | Therapeutic Targets in Telomerase and Telomere Biology of Cancers |
| Q42016940 | Thyroid transcription factor FOXE1 interacts with ETS factor ELK1 to co-regulate TERT. |
| Q26853261 | Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma |
| Q50072573 | Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation |
| Q91107708 | Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms |
| Q26739925 | Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene |
| Q90917856 | Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation |
| Q34483345 | Trial Watch: Peptide-based anticancer vaccines |
| Q47185839 | Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations |
| Q38760235 | Understanding TERT Promoter Mutations: A Common Path to Immortality. |
| Q92539491 | Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study |
| Q52662392 | When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM. |
| Q47725702 | Whole Genome Sequencing Analysis for Cancer Genomics and Precision Medicine. |
| Q88910053 | Whole-Genome Sequencing in Cancer |
| Q91793916 | cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV" |
| Q90672822 | hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality |
| Q53682892 | mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression. |
| Q108120135 | Reproductive guilds (maturation, spawning frequency and fecundity pomfret, parastromateus niger (Caranguidae) in the Kuwaiti water Gulf | main subject | P921 |
Search more.